GAIN THERAPEUTICS INC (GANX:NASDAQ)
$1.86 0.11 (6.2857%)
Analysed GAIN THERAPEUTICS INC (GANX:NASDAQ) News Sources
3 US Biotechs Developing Parkinson’s Therapies
05-05-2026
yahoo.com
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
11-05-2026
yahoo.com
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss
11-05-2026
advfn.com
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
22-05-2026
yahoo.com
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
26-05-2026
yahoo.com
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
27-05-2026
yahoo.com
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
10-06-2026
yahoo.com
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
29-06-2026
yahoo.com
Why Is GANX Stock Rallying 22% After Hours?
29-06-2026
stocktwits.com
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16-07-2026
yahoo.com
What is the current price of GAIN THERAPEUTICS INC (GANX:NASDAQ)?
The current price of GAIN THERAPEUTICS INC (GANX:NASDAQ) is $1.86.
GAIN THERAPEUTICS INC (GANX:NASDAQ) absolute price change since previous trading day?
The absolute price change of GAIN THERAPEUTICS INC (GANX:NASDAQ) since the previous trading day is $0.11.
GAIN THERAPEUTICS INC (GANX:NASDAQ) percentage price change since previous trading day?
The percentage price change of GAIN THERAPEUTICS INC (GANX:NASDAQ) since the previous trading day is 6.2857%.
What is the most recent average sentiment score for GAIN THERAPEUTICS INC (GANX:NASDAQ)?
The most recent average sentiment score for GAIN THERAPEUTICS INC (GANX:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for GAIN THERAPEUTICS INC (GANX:NASDAQ)?
The most recent sentiment for GAIN THERAPEUTICS INC (GANX:NASDAQ) is .
SEC-8K** Filing Available For GAIN THERAPEUTICS INC (GANX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.